Wellington Management Group LLP Buys 1,660 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Wellington Management Group LLP boosted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 15.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,680 shares of the company’s stock after buying an additional 1,660 shares during the quarter. Wellington Management Group LLP’s holdings in Krystal Biotech were worth $2,308,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Key Financial Inc bought a new stake in shares of Krystal Biotech during the 2nd quarter worth approximately $28,000. Blue Trust Inc. increased its stake in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares during the period. Values First Advisors Inc. bought a new stake in shares of Krystal Biotech during the third quarter worth $53,000. Quest Partners LLC purchased a new stake in shares of Krystal Biotech during the second quarter valued at $71,000. Finally, GAMMA Investing LLC grew its holdings in shares of Krystal Biotech by 184.8% in the third quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock worth $78,000 after purchasing an additional 279 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on KRYS shares. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Stifel Nicolaus lifted their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday. Finally, Citigroup increased their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Stock Down 7.3 %

Krystal Biotech stock opened at $156.64 on Thursday. The firm has a market cap of $4.51 billion, a P/E ratio of 88.50 and a beta of 0.80. The business has a fifty day moving average of $180.70 and a two-hundred day moving average of $185.17. Krystal Biotech, Inc. has a twelve month low of $107.50 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.67) earnings per share. Equities analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).